These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15146030)

  • 1. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
    Clozel M; Binkert C; Birker-Robaczewska M; Boukhadra C; Ding SS; Fischli W; Hess P; Mathys B; Morrison K; Müller C; Müller C; Nayler O; Qiu C; Rey M; Scherz MW; Velker J; Weller T; Xi JF; Ziltener P
    J Pharmacol Exp Ther; 2004 Oct; 311(1):204-12. PubMed ID: 15146030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.
    Behm DJ; McAtee JJ; Dodson JW; Neeb MJ; Fries HE; Evans CA; Hernandez RR; Hoffman KD; Harrison SM; Lai JM; Wu C; Aiyar NV; Ohlstein EH; Douglas SA
    Br J Pharmacol; 2008 Oct; 155(3):374-86. PubMed ID: 18587423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of urotensin II and its receptor in health and disease.
    McDonald J; Batuwangala M; Lambert DG
    J Anesth; 2007; 21(3):378-89. PubMed ID: 17680191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
    Trebicka J; Leifeld L; Hennenberg M; Biecker E; Eckhardt A; Fischer N; Pröbsting AS; Clemens C; Lammert F; Sauerbruch T; Heller J
    Hepatology; 2008 Apr; 47(4):1264-76. PubMed ID: 18318439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
    Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
    Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.
    Rossowski WJ; Cheng BL; Taylor JE; Datta R; Coy DH
    Eur J Pharmacol; 2002 Mar; 438(3):159-70. PubMed ID: 11909607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats.
    Clozel M; Hess P; Qiu C; Ding SS; Rey M
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1115-21. PubMed ID: 16267137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor.
    Tölle M; van der Giet M
    Peptides; 2008 May; 29(5):743-63. PubMed ID: 17935830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new ligand for the urotensin II receptor.
    Camarda V; Guerrini R; Kostenis E; Rizzi A; Calò G; Hattenberger A; Zucchini M; Salvadori S; Regoli D
    Br J Pharmacol; 2002 Oct; 137(3):311-4. PubMed ID: 12237249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urotensin receptor antagonist palosuran attenuates cyclosporine-a-induced nephrotoxicity in rats.
    Olukman M; Can C; Coşkunsever D; Uyanikgil Y; Çavuşoğlu T; Sözmen E; Duman S; Çelenk FG; Ülker S
    Adv Clin Exp Med; 2019 Oct; 28(10):1393-1401. PubMed ID: 31518496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
    Behm DJ; Harrison SM; Ao Z; Maniscalco K; Pickering SJ; Grau EV; Woods TN; Coatney RW; Doe CP; Willette RN; Johns DG; Douglas SA
    Br J Pharmacol; 2003 May; 139(2):464-72. PubMed ID: 12770952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury.
    Prosser HC; Forster ME; Richards AM; Pemberton CJ
    Peptides; 2008 May; 29(5):770-7. PubMed ID: 17900760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
    Camarda V; Song W; Marzola E; Spagnol M; Guerrini R; Salvadori S; Regoli D; Thompson JP; Rowbotham DJ; Behm DJ; Douglas SA; Calo' G; Lambert DG
    Eur J Pharmacol; 2004 Sep; 498(1-3):83-6. PubMed ID: 15363979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urotensin-II and UII-receptor expression and function in the rat adrenal cortex.
    Albertin G; Casale V; Ziolkowska A; Spinazzi R; Malendowicz LK; Rossi GP; Nussdorfer GG
    Int J Mol Med; 2006 Jun; 17(6):1111-5. PubMed ID: 16685423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.
    Behm DJ; Aiyar NV; Olzinski AR; McAtee JJ; Hilfiker MA; Dodson JW; Dowdell SE; Wang GZ; Goodman KB; Sehon CA; Harpel MR; Willette RN; Neeb MJ; Leach CA; Douglas SA
    Br J Pharmacol; 2010 Sep; 161(1):207-28. PubMed ID: 20718751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non peptidic urotensin II antagonists: perspectives for a new class of drugs.
    Cosenzi A
    Cardiovasc Hematol Agents Med Chem; 2008 Apr; 6(2):80-91. PubMed ID: 18473773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. Study in the perfused rat pancreas.
    Marco J; Egido EM; Hernández R; Silvestre RA
    Peptides; 2008 May; 29(5):852-8. PubMed ID: 17931748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
    Zhang R; Chen J; Liu D; Wang Y
    Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2009 Oct; 49(10):1168-75. PubMed ID: 19625629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel and Highly Potent Urotensin II Receptor Antagonist Inhibits Urotensin II-Induced Pressure Response in Mice.
    Nishi M; Yonesu K; Tagawa H; Kato M; Marumoto S; Nagayama T
    J Cardiovasc Pharmacol; 2019 Jan; 73(1):15-21. PubMed ID: 30608334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.